BMS 986177

Drug Profile

BMS 986177

Alternative Names: BMS986177

Latest Information Update: 25 Jul 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antithrombotics
  • Mechanism of Action Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Thrombosis

Most Recent Events

  • 30 Jun 2017 Bristol-Myers Squibb plans a pharmacokinetic phase I trial for Thrombosis (In adults, In the elderly, In volunteers) (PO)(NCT03196206)
  • 28 Jun 2017 Bristol-Myers Squibb initiates enrolment in a phase I trial for Thrombosis in USA (NCT03224260)
  • 23 May 2017 Phase-I/II clinical trials in Thrombosis in USA (PO) (NCT03000673)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top